Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several claims are unsupported or not supported by the provided FDA label excerpts (notably Australian PBS/pricing details). Some drug-related claims (indication timing ≥5 years ≤48 hours, prescription-only style statements, medication class, and general mechanism concepts) cannot be verified from the supplied label text and would require sections not provided. However, key FDA-label-supported points present include treatment indication timing (≤48 hours) and antiviral/therapeutic context at a high level.
Category Scores
Accurate Statements
In Australia, Xofluza is approved for the treatment of acute uncomplicated influenza in individuals aged 12 years and older who have been symptomatic for no more than 48 hours.
Supported in principle by label excerpt 1.1 (acute uncomplicated influenza; symptomatic no more than 48 hours; age threshold stated as ≥5 years; timing ≤48 hours). Age limit stated as 12+ in the claim is not confirmed in provided excerpt.
The recommended dosage for Xofluza in Australia for uncomplicated influenza is typically a single oral dose of 80 mg.
Supported in principle by label excerpt 2.2 (single weight-based dose; ≥80 kg = 80 mg once), but the claim omits weight-based selection details and asserts “typically 80 mg” without label support.
Xofluza offers a single-dose treatment regimen.
Supported by label excerpt 2.2 (single dose for treatment; single weight-based dose within 48 hours).
Xofluza is an antiviral medication.
Supported by the label excerpts’ context of influenza treatment and mechanism/clinical studies (e.g., indications for influenza and mechanism discussion in 12.4), though the label excerpt provided does not explicitly use the phrase “antiviral.”
Unsupported Statements
The price of Xofluza in Australia varies depending on the specific dosage, the pharmacy, and whether it is covered by the Pharmaceutical Benefits Scheme (PBS).
Not supported by the provided FDA prescribing information excerpts (PBS/pricing information is not part of the supplied label text).
Without PBS subsidy, the cost of Xofluza can be several hundred Australian dollars for a single 80 mg dose.
Not supported by the provided FDA prescribing information excerpts.
Xofluza is listed on the PBS in Australia for specific indications.
Not supported by the provided FDA prescribing information excerpts.
To be eligible for PBS subsidy, a patient must meet criteria determined by their prescribing doctor and PBS guidelines.
Not supported by the provided FDA prescribing information excerpts.
PBS eligibility typically involves treatment for uncomplicated influenza in individuals aged 12 years and older who have had symptoms for no more than 48 hours.
Not supported by the provided FDA prescribing information excerpts and includes a PBS-specific age threshold not present in the supplied label excerpt.
Xofluza is a prescription-only medication in Australia.
The provided FDA label excerpts do not address prescription-only status in Australia.
Xofluza can only be obtained from licensed pharmacies in Australia upon presentation of a valid prescription from a registered medical practitioner.
Not supported by the provided FDA prescribing information excerpts.
Xofluza works by inhibiting cap-dependent endonuclease activity of the influenza virus polymerase acidic protein.
The provided label excerpt references mechanism context in 12.4, but the specific mechanism wording (cap-dependent endonuclease of PA) is not included in the supplied text.
The inhibited enzyme is crucial for viral replication.
Not stated in the provided label excerpts.
By blocking this enzyme, Xofluza prevents the virus from making new copies of itself.
Not stated in the provided label excerpts as phrased.
By blocking this enzyme, Xofluza reduces the duration and severity of influenza symptoms.
The provided label excerpt indicates a statistically significant shorter time to alleviation of symptoms (14.1/14.2) but does not support “severity” language as stated, nor the enzyme-to-effect causal phrasing.
The specific dosage may be adjusted by a healthcare professional based on individual patient factors and the nature of the infection.
The provided label excerpt specifies a single weight-based dose and timing; it does not state dose adjustment based on individualized factors.
Common side effects associated with Xofluza may include diarrhea, bronchitis, nausea, vomiting, sinusitis, and headache.
The provided label excerpts do not list these specific “common side effects.” Trial-specific adverse event lists are referenced but not included in the provided text.
Less common but potentially serious side effects of Xofluza can also occur.
General statement is not supported or not supportable from the provided excerpts as phrased (no frequency grading or “less common but serious” list included).
Xofluza's mechanism of action differs from neuraminidase inhibitors.
The provided label excerpts do not explicitly compare to neuraminidase inhibitors mechanistically.
Contradictions
Low
AI Statement
PBS eligibility typically involves treatment for uncomplicated influenza in individuals aged 12 years and older who have had symptoms for no more than 48 hours.
Label Reference
FDA label excerpt 1.1 indicates treatment in patients 5 years of age and older (timing ≤48 hours). The claim’s “12 years and older” threshold is not supported by the provided label excerpt and may contradict the broader label age indication (≥5 years).
Important Omissions
PBS/drug-access claims were made without any support from FDA label content; inclusion of FDA label-relevant content (e.g., indication scope, dosing weight bands, and safety risks such as hypersensitivity and bacterial infection risk) was incomplete.
Importance:
Moderate
The FDA label contraindicates hypersensitivity to baloxavir marboxil/ingredients; the response list provided by the user does not include contraindication content.
Importance:
Moderate
Warnings in the label include increased incidence of treatment-emergent resistance in patients <5 years of age and risk of bacterial infections; these are not reflected in the user’s claim set.
Importance:
Moderate
Drug interaction guidance (avoid dairy products/polyvalent cations such as calcium/magnesium/iron and certain antacids/supplements) is not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some safety-relevant FDA label content (contraindications, hypersensitivity, bacterial infection risk, and interaction avoidance with polyvalent cations/dairy) was omitted, and several adverse-effect details were unsupported. These issues could lead to incomplete safety understanding if used as the source.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple non-label Australia/PBS/pricing/access claims and unsupported mechanism/side-effect specifics; FDA label-relevant safety and interaction information omitted.
Suggested Improvement
Remove/avoid PBS pricing and Australia regulatory-access assertions unless supported by the provided FDA label text; align indication and timing to FDA label (≥5 years for treatment with symptoms ≤48 hours, and include weight-based dosing details); cite label-supported adverse reactions/warnings/interactions or omit them.